Gina Mauro

Patients with mantle cell lymphoma in first complete response with undetectable MRD did not benefit from consolidative autologous transplant, according to results from the ECOG-ACRIN EA4151/BMT-CTN 1601 trial.

Treatment with epcoritamab alone demonstrated deep responses in heavily pretreated patients with CLL, according to the expansion and optimization cohorts in the EPCORE CLL-1 trial.

Approximately one-third of patients with pancreatic cancer and anxiety had a palliative care consultation, data showed.

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

While adjuvant pembrolizumab and chemotherapy with or without radiation did not boost DFS in the overall high-risk endometrial cancer population, but showed a trend toward improved DFS in one patient subgroup.

Pregnancies may be carried out and were successful in patients after undergoing allogeneic hematopoietic cell transplantation.

This analysis of patients with previously treated advanced clear cell renal cell carcinoma treated with belzutifan is the largest pooled safety dataset for a HIF-2α inhibitor.

Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.

Treatment with acalabrutinib and bendamustine/rituximab in the frontline setting improved progression-free survival in older patients with MCL.

Patients with newly diagnosed, high-risk acute promyelocytic leukemia treated with a combination strategy of ATO plus ATRA and idarubicin experienced improvements in event-free survival.

These data from the COMBI-AD trial represent the longest follow-up to date of adjuvant treatment for stage III melanoma.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

Encouraging responses were observed in most patients with relapsed/refractory follicular lymphoma treated with loncastuximab tesirine and rituximab.

Patients in the CARTITUDE-4 trial experienced a high response rate to the treatment as early as their first relapse.

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Trial data support potential treatment options with durvalumab-based regimens for advanced or recurrent endometrial cancer.

Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.

A supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) has been approved by the FDA at a reduced dose of 1.5 mg/kg every 2 weeks for the treatment of patients with relapsed/refractory multiple myeloma who have maintained a complete response or greater for at least 6 months.

Neoadjuvant treatment with camrelizumab plus nab-paclitaxel and cisplatin improved pathologic complete responses compared with chemotherapy alone in patients with esophageal squamous cell carcinoma.

Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.

The 5-year event-free survival rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab, compared with 72.3% in those who received placebo/chemotherapy plus placebo.

The median overall survival with pembrolizumab/olaparib was 25.1 months vs 23.4 months with pembrolizumab plus chemotherapy.

Leveraging circulating tumor (ct)DNA may help expedite the time to treatment and enhance survival prospects for individuals with lung cancer.

The FDA has approved fruquintinib to treat adults with metastatic colorectal cancer.

The median progression-free survival was not reached with selpercatinib vs 16.8 months with other kinase inhibitors.

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Mirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator's choice chemotherapy.

The 3 year-pelvic recurrence rates with simple hysterectomy were comparable with those of radical hysterectomy among patients with low-risk, early-stage cervical cancer.

Minimally invasive distal pancreatectomy was a safe and effective alternative compared with open distal pancreatectomy in patients with resectable pancreatic cancer.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.